Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics to Present Company Overview at the UBS Global Healthcare Conference on May 20

Business Wire May 16, 2014

Sarepta Therapeutics Announces First Quarter 2014 Financial Results and Recent Corporate Developments

Business Wire May 8, 2014

Sarepta Therapeutics to Present Company Overview at the 2014 Bank of America Merrill Lynch Healthcare Conference

Business Wire May 6, 2014

Sarepta Therapeutics to Present Company Overview at the 2014 39th Annual Deutsche Bank Healthcare Conference

Business Wire April 29, 2014

Sarepta Therapeutics to Announce First Quarter 2014 Financial Results and Corporate Update on May 8, 2014

Business Wire April 29, 2014

Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on May 13, 2014

Business Wire April 28, 2014

Sarepta Therapeutics Announces Pricing of $100.7 Million Public Offering of Common Stock

Business Wire April 23, 2014

Sarepta Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire April 22, 2014

Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy by Year End 2014

Business Wire April 21, 2014

Top Gainers Technical Data -- Research on BGC Partners, Sarepta Therapeutics, TripAdvisor, and LiveDeal

PR Newswire April 2, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014

Business Wire March 26, 2014

Sarepta Therapeutics to Present Company Overview at the 2014 Needham Healthcare Conference

Business Wire March 26, 2014

Apply Market Savvy to Bear Market Debris; Uncover Biotech Treasures: Cleland and Ireland

Equities.com March 24, 2014

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline (SRPT)

GlobeNewswire March 22, 2014

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014

Business Wire March 19, 2014

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT

GlobeNewswire March 14, 2014

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT

GlobeNewswire March 7, 2014

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT

PR Newswire March 4, 2014

SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers - SRPT

PR Newswire February 28, 2014

Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments

Business Wire February 27, 2014